PHAP1 (Putative HLA-DR-associated protein 1), also termed acidic leucine-rich nuclear phosphoprotein 32A (ANP32A), Phosphoprotein 32 (pp32) or protein phosphatase 2A inhibitor (I1PP2A), is a multifunctional protein aberrantly expressed in multiple types of human cancers. However, its expression pattern and clinical relevance in human glioma remain unknown. In this study, Western blotting and immunohistochemistry analysis demonstrated PHAP1 protein was highly expressed in glioma patients, especially in those with high-grade disease. Publicly available data also revealed high levels of PHAP1 were associated with poor prognosis in glioma patients. The functional studies showed that knock-down of PHAP1 suppressed the proliferation of glioma cells, while overexpression of PHAP1 facilitated it. The iTRAQ proteomic analysis suggested that stathmin might be a potential downstream target of PHAP1. Consistently, PHAP1 knock-down significantly decreased the expression of stathmin, while overexpression of PHAP1 increased it. Also, the upstream negative regulator, p27, expression levels increased upon PHAP1 knockdown and decreased when PHAP1 was overexpressed. As a result, the phosphorylated Akt (S473), an upstream regulator of p27, expression levels decreased upon silencing of PHAP1, but elevated after PHAP1 overexpression. Importantly, we demonstrate the p27 down-regulation, stathmin up-regulation and cell proliferation acceleration induced by PHAP1 overexpression were dependent on Akt activation.
| INTRODUCTION
Glioma is the most common form of primary tumour that originates from the central nervous system. 1 In line with the classification criteria of the World Health Organization (WHO), glioma is classified into lower grades (Grade I and II) and higher grades (Grade III and IV). 2 In spite of significant progression in surgery and adjunctive therapy, the prognosis of glioma patients remains poor. The reported median survival time for patients diagnosed with glioma is about 15 months where less than 3 percent have a 5-year survival rate. 3 Therefore, investigating the mechanisms underlying gliomagenesis is critical to identify new biomarkers for earlier diagnostics, as well as develop novel targeted therapies to combat this highly malignant disease.
PHAP1 is a nuclear phosphoprotein that plays a variety of cellular roles in cell differentiation, gene transcription, cell apoptosis and cell cycle transition. [4] [5] [6] Recent studies have shown PHAP1 plays important roles in human cancers. Most of the studies show that PHAP1 functions as a tumour suppressor in human breast cancer, pancreatic cancer and non-small-cell lung cancer. [7] [8] [9] However, other reports demonstrate increased PHAP1 expression is linked to hepatocellular carcinoma, colorectal cancer, prostate cancers and oral squamous cell carcinoma, [10] [11] [12] [13] [14] Stathmin, as a mitotic regulator, plays important roles in maintaining the biological characteristics of the cells through controlling rapid microtubule remodelling. 16, 17 Studies have shown that stathmin is expressed increasingly in several human malignancies, including leukaemia, mesothelioma, neuroblastoma and glioma. 18, 19 Previous groups have reported that stathmin is negatively regulated by the cell cycle inhibitor p27. 20 Moreover, Akt is a main regulator responsible for the modulation of p27. 21 Based on the above findings, we hypothesized PHAP1 may regulate stathmin through the Akt/p27
pathway.
In this study, we investigate the role of PHAP1 in human glioma cells by assessing the expression of PHAP1 protein in glioma tissues and cell lines using Western blotting and immunohistochemistry analysis. Additionally, we determine PHAP1 plays a significant role in glioma cell proliferation. Finally, we explore the effects of PHAP1 on Akt/p27 regulated stathmin signalling. 
| Constructs and production of the lentivirus
To knock-down PHAP1, three sets of shRNA duplexes were designed and synthesized as the followings:
shPHAP1-F1: 
The PHAP1 shRNAs and control shRNA oligomers were annealed and then cloned into the pLV-shRNA plasmid using the BamH I and EcoR I cloning sites. To overexpress PHAP1 in glioma cells, the PHAP1 cDNA was cloned into the pWPXLd-puro plasmid by using BamH I and Mlu I enzyme sites. Cell transfection was carried out by PolyJet (SignaGen, Gaithersburg, MD, USA) according to the manufacturer's instructions. The lentiviruses were produced by cotransfecting the core plasmid and the packaging plasmids in 293T cells.
| Development of the stable cell lines
The stable cell lines were developed as we previously described. [22] [23] [24] For stably knocking down or overexpressing PHAP1, the U251 and U87 cells were infected with the control, shPHAP1#3, GFP or GFP-PHAP1 lentiviruses, respectively. Forty-eight hours after infection, the cells were continuously provided with the medium supplemented with 2.5 lg/mL puromycin (Sigma, St. Louis, MO, USA). The survived cells were developed into stable cell lines that express control shRNA, shPHAP1 #3, GFP or GFP-PHAP1. ing the ratios between experimental group and control group. To make the data more credible, the iTRAQ experiment was repeated at three times. The changes were considered significant if the increased or decreased fold change >1.5 and the P-value <.05. The original mass spectrum data were searched by database using Mascot 2.2 and Proteome Discoverer 1.4 (Thermo Fisher Scientific, CA, USA).
| Quantitative iTRAQ-based proteomic analysis

| EdU assay
The cells stably knocking down or overexpressing PHAP1 were cultivated in 96-well plates at 4 9 10 3 cells/well. Twenty hours after culture, the cells were applied to 50 lmol/L of 5-ethynyl-20-deoxyuridine (EdU; Ribobio, Guangzhou, China) and incubated for 2 hours at 37°C. The cells were washed with PBS and fixed with 4% paraformaldehyde for 20 minutes, and then permeabilized with 0.5% Triton X-100 for another 20 minutes. Afterwards, the cells were washed five times with PBS and incubated with 100 lL of 1 9 Apolloâ reaction cocktail for 30 minutes at room temperature.
Finally, the nuclei of the cells were dyed with 100 lL of Hoechst 33342 (5 lg/mL) for 20 minutes and visualized with a fluorescent microscopy (IX71; Olympus, Tokyo, Japan).
| Colony formation assay
The plate colony formation assay was carried as we previously described. 22-24 5 mL of cell suspension containing 200 cells was inoculated into a diameter 60 mm dish for continuous culture until the visible clones appeared. After washing with PBS, the cells were fixed with 100% methanol. Afterwards, the cells were incubated with 0.5% crystal violet to subject for colony staining. Finally, the dishes were dried naturally and photographed with a camera for colony counting.
| CCK-8 assay
Two thousand cells in 100 lL of medium were cultured in several 96-well plates. At the designated time-point, 10 lL of CCK-8 reagent was applied into the medium. After reaction for 4 hours at 37°C, the absorbance at 450 nm was determined by a SynergyMx
Multi-Mode Microplate Reader (Biotek, Winooski, VT). The cell viability was calculated according to the absorbance.
| Western blotting
At the designated time-point, the cells were harvested and subjected for total protein extraction. To analyse the protein expression by Western blotting, equal amounts of proteins were isolated on a 12% SDS-PAGE and then transferred to 0.45 lm pore size PVDF membrane (Millipore, Billerica, MA, USA). After blocking with 3% bovine serum albumin (BSA), the membrane was incubated with the primary antibodies (PHAP1, Stathmin, Akt, Akt (S473), p27 and b-actin) at 4°C overnight. On the following day, the membranes were probed with a horseradish peroxidase (HRP)-labelled goat anti-rabbit/mouse IgG. 
| Statistical analysis
The results shown were representative of experiments that were repeated at least three times. All quantitative data were presented 3 | RESULTS
| PHAP1 protein is up-regulated in human glioma patients and glioma cells
To study the role of PHAP1 in the development of human gliomas, the total protein was isolated from 30 cases of human glioma tissue F I G U R E 1 Expression of PHAP1 in human glioma patients and glioma cell lines. A, Total proteins isolated from non-neoplastic brain tissues and glioma tissues were analysed by Western blotting for assessment of PHAPl. B, Statistical chart showed the expression level of PHAP1 in non-tumourous brain tissue and the different grades of glioma tissues. The ratios indicate the levels of PHAP1 to b-actin levels with respect to each sample. C, Expression of PHAP1 in non-tumourous cell line (293T) and glioma cell lines (C6, U251, U118, A172, U87). D, Representative images and E, quantification of the immunohistochemical analysis showed PHAP1 was up-regulated in human glioma patients. F, Kaplan-Meier analysis with TCGA database showed higher level of PHAP1 was associated with poorer survival outcome in glioma patients. Scale bars: 50 lm. * , P < .05; * * , P < .01; * * * , P < .001 Figure 1A showed down-regulation of PHAP1-inhibited glioma cell proliferation in U251 and U87 cells. E, EdU incorporation assay, colony formation assay F, and CCK-8 assay (G and H) showed overexpression of PHAP1-promoted glioma cell proliferation in U251 and U87 cells highly expressed in human gliomas, providing initial evidence that PHAP1 may play an important role in the development and progression of human gliomas.
| The effects of PHAP1 on glioma cell proliferation
To explore the roles of PHAP1 in glioma cell proliferation, we used specific shRNAs to down-regulate PHAP1 expression. To knockdown PHAP1, three shRNA targets (shPHAP1#1, shPHAP1#2 and shPHAP1#3) were examined for their efficacy in suppressing PHAP1 expression, and a non-targeting shRNA served as a negative control.
ShPHAP1#3 was the ideal candidate for silencing PHAP1 expression ( Figure S1A,B) . To develop stable cell lines with PHAP1 knock-down, shPHAP1#3 was used for lentivirus production and infection of the Figure 2B ). In addition, the CCK-8 assay showed the cell viability was reduced upon knocking down PHAP1 compared to the control group ( Figures 2C and D) .
Additionally, we overexpressed GFP-PHAP1 in U251 and U87 cells to further determine the function of PHAP1 in the proliferation of glioma cells. The expression efficiency of PHAP1 was confirmed by GFP images (Figure S2A,B) and Western blotting (Figure S2C,D) .
We then validated whether overexpression of PHAP1 could promote the cell proliferation. EdU incorporation assay showed that the number of proliferating cells of the GFP-PHAP1 group was increased in U251 and U87 cells by 34% and 62%, respectively, compared with GFP group ( Figure S2E ,F & Figure 2E ). The capability of colony formation was also significantly enhanced by overexpression of PHAP1 ( Figure S2G ,H & Figure 2F ). In addition, CCK-8 assay indicated that overexpression of PHAP1 significantly accelerated the proliferation of U251 and U87 cells compared to the control groups ( Figure 2G , H). These data suggest that PHAP1 is important for the proliferation of human glioma cells, and down-regulation of PHAP1 suppresses the proliferation of glioma cells, while overexpression of PHAP1 promotes it.
| Identification of proteins regulated by PHAP1 via quantitative proteomic analysis
The above results have indicated that PHAP1 is important for the proliferation of glioma cells. However, the underlined mechanisms
are not yet elucidated. Thus, we performed an iTRAQ proteomic analysis to compare the protein expression between control and shPHAP1#3 in both U251 and U87 cells. A total of 5400 peptides were detected in three independent biological replicates among four groups. Then, we analysed the identified peptides. As a result, 57
and 71 changed proteins were identified in U251 and U87 cells, respectively ( Figure 3A) . In U251 cells, there were 27 down- 3.4 | PHAP1 promotes glioma cell proliferation by regulating Akt/p27/stathmin pathway Previous reports show stathmin is negatively controlled by the cell cycle inhibitor p27. 20 Therefore, we assessed the expression of p27 in the PHAP1-modulated cells. As expected, the upstream negative regulator p27 was increased in PHAP1 down-regulated U251 and U87 cells, whereas decreased in PHAP1 overexpressed U251 and U87 cells (Figure 4A,B) . Consistently, phosphorylated Akt (S473), the upstream regulator of p27, was decreased upon knocking down PHAP1, but enhanced when PHAP1 was overexpressed ( Figure 4C,D Akt-dependent stathmin signalling, which facilitates glioma cell F I G U R E 5 Akt inhibitor significantly blocks PHAP1 overexpression-induced p27 down-regulation, stathmin up-regulation and cell proliferation. A, Representative blots and (B and C) quantification showed that Akt inhibitor MK-2206 effectively attenuated PHAP1 overexpression-induced p27 down-regulation and stathmin upregulation in U251 and U87 cells. D, EdU assay showed Akt inhibitor significantly blocked PHAP1 overexpression-induced glioma cell proliferation. *P < .05, **P < .01
proliferation. Therefore, aberrant expression of PHAP1 may be an important event in the development and malignant progression of glioma.
Stathmin regulates dynamic instability, the growth and shrinkage of microtubules by modulating microtubule plus end catastrophes and sequestering alpha-beta tubulin dimers. 40 Consequently, stathmin has direct effects on cellular processes including cell growth and motility by influencing the association of microtubules with the actin cytoskeleton. 41 Consistent with this, stathmin has been shown to play important roles in glioma cell growth and motility. 19, 42, 43 In our study, we found that the stathmin was significantly up-regulated upon PHAP1-induced activation of Akt pathway. Furthermore, the up-regulation of stathmin expression and acceleration of glioma cell proliferation induced by PHAP1 overexpression could be almostly blocked by Akt inhibitor. These results indicate that the up-regulation of stathmin expression and glioma cell proliferation acceleration induced by PHAP1 overexpression is mainly mediated by the Akt pathway.
In conclusion, we demonstrate how PHAP1 is linked to malignant proliferation of human glioma through the Akt/p27/stathmin pathway. Our work elucidates new findings that warrant further exploration of the PHAP1-mediated signalling pathway, as well as, evaluation of the prognostic potential of PHAP1 expression in glioma patients. However, deeper investigations are still needed to elaborate how PHAP1 to regulate the activation of Akt in human glioma in the future study.
